Clinical Trial

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to other standard treatment is: * Effective in improving survival * safe and tolerable
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-18; most recent amendment 2025-11-05.
Status change: Not Yet Recruiting → Recruiting 2025-10-19
Trial Details
NCT Number NCT07130903
Lead Sponsor Barbara Ann Karmanos Cancer Institute
Collaborators: THERABIONIC INC.
Conditions Metastatic Colorectal Adenocarcinoma
Enrollment 102 participants
Start Date 2025-09-10
Primary Completion 2028-04-17 (estimated)
Study Completion 2030-04-17 (estimated)
Updated on ClinicalTrials.gov 2025-11-10